Alpha Cognition reports Q1 2026 ZUNVEYL revenue of $3.5M, up 40%

Alpha Cognition Inc. (NASDAQ: ACOG) reported first quarter 2026 net product revenue of $3.5 million for its Alzheimer's treatment ZUNVEYL, representing a 40% increase from the fourth quarter of 2025, according to a press release statement.

The biopharmaceutical company dispensed 6,054 bottles of ZUNVEYL in the first quarter, marking a 23% quarter-over-quarter increase. March represented the strongest demand month since the drug's launch, with approximately 29% growth over February.

Cumulative net product revenue for ZUNVEYL totaled $10.3 million through the first four full quarters since launch. The company reported that approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization during the quarter.

Alpha Cognition's healthcare provider writers grew 23% quarter-over-quarter to 1,060, while the number of prescribers contacted expanded 93% to approximately 3,762. The sales team reached 2,502 unique nursing homes in the first quarter, 26% more than the fourth quarter.

The company posted a net loss of $6.5 million for the quarter ended March 31, 2026, compared to $1.7 million in the first quarter of 2025. Total operating expenses were approximately $11.6 million, reflecting investments in commercial infrastructure and clinical programs.

Cash and cash equivalents totaled $54.2 million as of March 31, 2026, down from $66.0 million at December 31, 2025. The company maintains its full-year 2026 operating expense guidance of approximately $54-58 million and targets operating profitability in 2027.

Alpha Cognition has Medicare Part D contracts with two major pharmacy benefit managers covering approximately 45 million lives. The BEACON clinical study enrollment is substantially complete, with topline data anticipated in early Q3 2026.

You May Also Be Interested In

• BIG3 Basketball to go public via Graf Global merger at $290 million
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Medtronic completes $550 million Scientia Vascular acquisition